dissection. That Greening and his colleagues are right in thinking that such a trial is both justifiable and ethical cannot be denied; it is the formidable difficultyand lapse of time before definite results can be seen which is daunting. Ifthe results ofthe limited operation proposed continue to be as good as they have hitherto been in the Royal Marsden series, the case would surely be proven in a shorter time. It is to be hoped that a further report on this series will emerge.
Two final points: First, it is, as Greening says, generally accepted 'that breast cancer is in most, if not all, cases a systemic disease at the time of diagnosis'. But this need not, in the early case, preclude the possibility of cure. The body has an immune surveillance mechanism which can deal with a light load and gives grounds for guarded optimism in the veryearly low grade case. Secondly, itdoes not seemproper that the surgeon who seesfew cases of breast cancer, and has no special interest in the disease or intention of a meticulous follow up, should embark on new procedures which remain unproven and on which he will be in no position to shed further light. The matter has, however, gone a lot further than this. In April 1977an agreement of intent on more stringent qualitative regulations was announced by the DHSS and the ABPI, which it was intended would be incorporated in the revised code of practice of the ABPI. The original code of practice which was issued in 1958 was formulated after consultation with the BMA. The new code will also take into consideration the views of the Department of Health and Social Security. Under the agreement of intent two classes of pharmaceutical advertising were recognized as previously: the full advertisement for new products, and the reminder advertisement for existing products (now renamed the abbreviated advertisement). Under the agreement it was laid down that the abbreviated advertisement would become limited in size, It would not be whole page in certain journals and had to be less than half page in others. Subsequently it transpired that it was the intention of the DHSS that any advertisement less than a whole page would not be more than half a page. Negotiations are still at a delicate stage on this point. Both the pharmaceutical industry and the medical publishers who were not consulted at the time of the agreement of intent are anxious for different reasons to preserve whole page advertising or single advertisements that occupy most of a page. The industry has reservations about the relative value of half-page advertising. These reservations could lead to a concentration of promotional expenditure on the full-page advertising of new products. If this does come about, it could result in new and more expensive drugs being prescribed at the expense of cheaper traditional remedies. In this case not only would the level of NHS drug expenditure rise, but the volume of advertising could fall still further, to the detriment of medical journals generally. The DHSS has listened to representatives from the medical publishers who are now more concerned at the potential situation than are the pharmaceutical industry. The whole question will have to be resolved before the revised code of practice can come into operation. Should the quality and quantity of professional advertising be an area of government activity and are the present proposals likely to achieve the original objectives of the Chancellor? Certainly there is no reason to believe that a reduction in advertising revenue will assist medical journals in their postgraduate role. It was against this background that the Medico-Pharmaceutical Forum meeting of I June 1977(seep 282)was held.
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